WHO, Critical Review, of the Antibacterial Pipeline (AAC ed.)

<p>AAC just published a review from the WHO advisory panel on the antibacterial pipeline analyzing ‘traditional’ and ‘non-traditional’ antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens, mycobacteria and Clostridioides difficile. Today, we will dissect this important publication</p> <p>Objectives:</p> <p>• Understand the role of the WHO in antimicrobial resistance<br /> • Discuss the analysis of the antibacterial pipeline<br /> • Deliberate on important highlights from the review and the future of antibacterial research.</p> <p>Guests:<br /> - Dr. Peter Beyer, Senior Advisor for the Antimicrobial Resistance Division at the World Health Organization.<br /> - Dr. Mark Butler, MSBChem Consulting, Brisbane, Queensland, Australia<br /> - Dr. Prabhavathi Fernandes. Member, Scientific Advisory Committee, GARDP, Geneva, Switzerlandand The National Biodefense Science 17Board, Health and Human Services, Washington DC, USA</p> <p>This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias. AAC is available at <a href= "https://aac.asm.org">https://aac.asm.org</a>. Follow Cesar on twitter at <a href= "https://twitter.com/SuperBugDoc">https://twitter.com/SuperBugDoc</a> for AAC updates.</p> <p>Subscribe to the podcast at <a href= "https://asm.org/eic">https://asm.org/eic</a></p>